Celavet Animal Health
Advancing Beyond Mainstream Stem Cell Technology
Celavet Inc., a subsidiary of Celavie Biosciences LLC, is a regenerative medicine company that develops stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals, restoring health and mobility.
We utilize Celavie’s technology transplanting allogeneic stem cells into the ligaments and tendons of injured horses, enabling them to regain their fullest potential as competitors, performers, workers, or companions.
Celavet offers a faster path to a global market for Celavie Biosciences, with close to 400 horses treated at more than 35 veterinary centers around the US in multiple trials. Results have thus far been promising in horses with chronic tendon and ligament injuries and disorders for which no existing treatments offered hope of recovery.
Celavet’s equine donor screening protocol and stem cell product characterization have been approved by the Center for Veterinary Medicine (CVM).
We expect to obtain approval by early 2021 for Target Animal Safety (TAS) and clinical controlled studies: (OK100 for the Treatment of Equine Musculoskeletal Injuries (INAD 011792)).